Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb

“Psoriasis Market”
As per DelveInsight, the Psoriasis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Psoriasis in the 7MM.

DelveInsight’s “Psoriasis Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psoriasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

 

The Psoriasis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

Key highlights from the Psoriasis Market Report:

 

  • In October 2023, the US FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.

  • The launch of potential therapies by key players AnaptysBio, MoonLake Immunotherapeutics, Takeda, Evelo Biosciences, UNION Therapeutics, and others are expected to boost the psoriasis market in the coming years.

  • AnaptysBio intends to out-license imsidolimab in 2024 and the company plans to present the data in second half of 2024 medical meeting.

  • In February 2023, Nimbus Therapeutics announced the closing of Takeda’s acquisition of Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.

  • In July 2020, the US FDA granted ODD for imsidolimab for treating patients with generalized pustular psoriasis.

  • Key Psoriasis Companies: Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others

  • Key Psoriasis Therapies: TLL018 tablets, Rimegepant, SFA002, BMS-986165, BMS-986322, VTX958, Apremilast, Risankizumab, ESK-001, DC-806, Bimekizumab, JNJ-77242113, Topical roflumilast, Imsidolimab, Tildrakizumab, Secukinumab, PF-07038124, Spesolimab, KBL697, Orticumab, ATI-450, and others

  • The Psoriasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriasis pipeline products will significantly revolutionize the Psoriasis market dynamics.

  • In June 2023, UCB, declared that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with the U.S. Food & Drug Administration (FDA). UCB previously communicated the FDA action was expected in Q2, 2023. UCB now anticipates the FDA action in Q3, 2023. There are no open Information Requests from the FDA regarding the BLA for bimekizumab.

 

Read detailed insights on Psoriasis market outlook 2034 @ https://www.delveinsight.com/sample-request/psoriasis-market

 

 

Psoriasis Overview

 

Psoriasis is a chronic autoimmune condition that affects the skin, causing inflammation, redness, and the development of scaly patches. This widespread disorder impacts millions of people worldwide. The core issue in psoriasis is an overactive immune response that accelerates the skin cell growth cycle, leading to the rapid buildup of thick, silvery scales on the skin’s surface. While symptoms can vary, common signs include red patches covered with thick, white or silvery scales, itching, burning sensations, dry and cracked skin that may bleed, and swollen, stiff joints. Psoriasis can appear anywhere on the body but commonly affects areas such as the elbows, knees, scalp, lower back, and nails.

 

The exact cause of psoriasis is not fully understood, but it is thought to result from a combination of genetic factors and environmental triggers. Diagnosis typically involves a dermatologist evaluating the affected skin and reviewing the patient’s medical history. Although no specific diagnostic test exists for psoriasis, a skin biopsy may be performed to exclude other skin conditions. The severity of psoriasis is often assessed using various classification systems that consider the extent of skin involvement and the impact on the patient’s quality of life.

 

Psoriasis Epidemiology Insights:

  • Psoriasis is a widespread condition with a global prevalence ranging from 1% to 8%, and approximately one-third of cases begin in childhood.

  • In 2023, the total number of diagnosed psoriasis cases in the US was estimated to be around 8 million.

  • Among type-specific cases, plaque psoriasis is the most common, affecting approximately 68% of patients, followed by inverse psoriasis.

  • In 2023, about 28% of psoriasis patients in the US were estimated to have genital psoriasis, with scalp psoriasis being another prevalent form.

  • Plaque psoriasis is the most common type, affecting about 90% of psoriasis patients, with 20%–30% experiencing moderate to severe forms.

  • A study by Armstrong et al. (2021) examined the prevalence of psoriasis among adults in the US and noted trends since 2003. The study found a 3.0% prevalence rate for adults, while the prevalence among children under 18 years was approximately 0.128%.

 

Psoriasis Therapies

  • TLL018 tablets

  • Rimegepant

  • SFA002

  • BMS-986165

  • BMS-986322

  • VTX958

  • Apremilast

  • Risankizumab

  • ESK-001

  • DC-806

  • Bimekizumab

  • JNJ-77242113

  • Topical roflumilast

  • Imsidolimab

  • Tildrakizumab

  • Secukinumab

  • PF-07038124

  • Spesolimab

  • KBL697

  • Orticumab

  • ATI-450

Psoriasis Key Companies

  • Hangzhou Highlightll Pharmaceutical Co. Ltd

  • Biohaven Pharmaceuticals, Inc.

  • SFA Therapeutics

  • Bristol-Myers Squibb

  • Ventyx Biosciences, Inc

  • Amgen

  • AbbVie

  • Alumis Inc

  • DICE Therapeutics, Inc.

  • UCB Pharma

  • Janssen Research & Development, LLC

  • Arcutis Biotherapeutics, Inc.

  • AnaptysBio, Inc.

  • Sun Pharmaceutical Industries Limited

  • Novartis

  • Pfizer

  • Boehringer Ingelheim

  • KoBioLabs

  • Abcentra

  • Aclaris Therapeutics

 

 

Learn How the Psoriasis Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/psoriasis-market

 

 

Psoriasis Market Outlook

Psoriasis is a chronic, relapsing skin condition requiring ongoing management, influenced by disease severity, comorbidities, and healthcare access. Patients are generally classified into mild or moderate-to-severe categories based on lesion severity, affected body surface area, and quality of life impact. The psoriasis treatment market is largely driven by TNF inhibitors, interleukin inhibitors, and vitamin D analogs, with growth fueled by the adoption of biologics, precision medicine, and expanded topical treatments. Recent market developments include the approval of oral TYK2 inhibitors and nonsteroidal topical agents, increasing competition.

 

Key psoriasis treatments include:

 

– BIMZELX (bimekizumab-bkzx): A monoclonal antibody targeting moderate to severe plaque psoriasis by inhibiting IL-17A and IL-17F. Approved by the US FDA in October 2023 for adults needing systemic or phototherapy.

  

– ENBREL (etanercept): A TNF blocker that combines the TNF receptor’s ligand-binding portion with human IgG1’s Fc portion.

  

– REMICADE (infliximab): A TNF blocker for severe adult plaque psoriasis, consisting of a chimeric IgG1κ monoclonal antibody with both human and murine components.

  

– HUMIRA (adalimumab): A recombinant human IgG1 monoclonal antibody created through phage display technology, combining human-derived and human constant regions.

  

– STELARA (ustekinumab): Targets IL-12 and IL-23 cytokines using a human IgG1κ monoclonal antibody, produced through recombinant DNA technology.

  

– COSENTYX (secukinumab): A human biologic that inhibits IL-17A, impacting various conditions including psoriatic arthritis and moderate to severe plaque psoriasis.

 

 

Psoriasis Treatment Market

 

A variety of treatments are available for managing psoriasis symptoms. For mild-to-moderate cases, topical therapies are typically used. These treatments aim to modulate gene transcription, inhibit cell proliferation, and promote keratinocyte differentiation. Common topical options include glucocorticoids, vitamin D analogs, and phototherapy. Notable agents in this category are corticosteroids, retinoids such as tazarotene, calcineurin inhibitors like tacrolimus, and vitamin D analogs such as calcipotriene and calcitriol. Combination therapies, such as calcipotriene with betamethasone dipropionate, are also used.

 

For patients who do not respond adequately to traditional systemic therapies, or who experience adverse effects or have comorbidities that make such therapies unsuitable, biologics offer a potent alternative. These advanced treatments target specific immune system components involved in psoriasis.

 

Several biosimilars are available for treating psoriasis and psoriatic arthritis, providing options similar to established biologics. Biosimilars to HUMIRA (adalimumab) include AMJEVITA (adalimumab-atto), ABRILADA (adalimumab-afzb), CYLTEZO (adalimumab-adbm), HADLIMA (adalimumab-bwwd), HULIO (adalimumab-fkjp), and HYRIMOZ (adalimumab-adaz). For ENBREL (etanercept), biosimilars include ERELZI (etanercept-szzs) and ETICOVO (etanercept-ykro). Biosimilars for REMICADE (infliximab) are AVSOLA (infliximab-axxq), INFLECTRA (infliximab-dyyb), IXIFI (infliximab-qbtx), and RENFLEXIS (infliximab-abda).

 

Leading Players in the Psoriasis Therapeutics Market Include:

Psoriasis Companies working in the market are Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb, Ventyx Biosciences, Inc, Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others.

 

Psoriasis Report Covers the In-depth Assessment of the Emerging Psoriasis Drugs & Key Companies. Download the Psoriasis Market Sample Report to Learn More @ https://www.delveinsight.com/sample-request/psoriasis-market

 

Table of Contents

 

1. Key Insights

2. Executive Summary 

3. Psoriasis Competitive Intelligence Analysis

4. Psoriasis Market Overview at a Glance

5. Psoriasis Disease Background and Overview

6. Psoriasis Patient Journey

7. Psoriasis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Psoriasis Treatment Algorithm, Current Treatment, and Medical Practices

9. Psoriasis Unmet Needs

10. Key Endpoints of Psoriasis Treatment

11. Psoriasis Marketed Products

12. Psoriasis Emerging Drugs and Latest Therapeutic Advances

13. Psoriasis Seven Major Market Analysis

14. Attribute Analysis

15. Psoriasis Market Outlook (In US, EU5, and Japan)

16. Psoriasis Access and Reimbursement Overview

17. KOL Views on the Psoriasis Market

18. Psoriasis Market Drivers

19. Psoriasis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market  | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb